Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding.
Richard F MacLehoseNeil A ZakaiRob F WalkerAlvaro AlonsoTerrence AdamsPamela L LutseyPublished in: Research and practice in thrombosis and haemostasis (2021)
We found modest evidence of decreased risk of bleeding for apixaban and rivaroxaban. These estimates were relatively imprecise.